Monod Bio licenses AI proteins to SignalChem
Analysis based on 9 articles · First reported Jul 20, 2026 · Last updated Aug 26, 2026
The licensing agreement is a modest positive for Sino Biological, expanding its service offerings with AI-designed protein technologies, though the company stated the revenue impact is not material. For Monod Bio, the deal validates its Monod Inside model and expands the reach of its platform into commercial services, potentially enhancing its attractiveness to future partners and investors.
Monod Bio, a Seattle-based AI-enabled protein design company, and SignalChem Biotech Inc., a wholly-owned subsidiary of Sino Biological, Inc. (SZSE: 301047), announced a non-exclusive licensing agreement on August 26, 2026. Under the agreement, SignalChem Biotech may incorporate Monod Bio's proprietary LuxSit de novo luciferase technology and NovoBodies into custom luminescent assay development and protein-fusion services offered to third-party customers for research use. The collaboration expands SignalChem's specialized CRO capabilities and supports Sino Biological's broader strategy of incorporating AI-enabled technologies across its global life science tools and services portfolio. Monod Bio's LuxSit is an AI-designed luciferase engineered for use in robust luminescent biosensors, while its NovoBodies are compact, highly stable binding proteins engineered for high-performance recognition of various targets. The companies noted that the revenue associated with this business is not expected to have a material impact on Sino Biological's overall financial performance.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard